iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 9:00AM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients,
today announced that Michel Detheux, Ph.D., President and Chief
Executive Officer, will present at the 42nd Annual J.P. Morgan
Healthcare Conference being held in San Francisco, CA on Wednesday,
January 10, 2024 at 3:00 p.m. PST (6:00 p.m. EST).
A live webcast of the presentation will be
available on the Investors section of the Company’s website at
https://www.iteostherapeutics.com. An archived replay will be
available for approximately 30 days following the presentation.
About iTeos Therapeutics,
Inc.
iTeos Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to restore the immune response
against cancer. The Company’s innovative pipeline includes three
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes, including the TIGIT:CD226 axis and the
adenosine pathway. iTeos Therapeutics is headquartered in
Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of
Information
iTeos Therapeutics routinely posts information
that may be important to investors in the 'Investors' section of
its website at www.iteostherapeutics.com. The company encourages
investors and potential investors to consult our website regularly
for important information about iTeos Therapeutics.
For further information, please
contact:
Investor Contact:
Carl MauchiTeos Therapeutics,
Inc.carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
iTeos Therapeutics (NASDAQ:ITOS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024